COM701 Shows Promise in Treating Ovarian, Other Solid Tumors, Early Data Suggest

COM701 Shows Promise in Treating Ovarian, Other Solid Tumors, Early Data Suggest
Treatment with Compugen's immune checkpoint inhibitor COM701, either alone or in combination with Opdivo (nivolumab), is well-tolerated in people with advanced solid tumors, including ovarian cancer, early Phase 1 trial results show. The findings were presented in a poster, "A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients With Advanced Solid Malignancies," at the recent ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida. Immune checkpoint proteins tell the immune system what is normal and what is abnormal. Cancer cells, however, hijack this checkpoint system and produce proteins that bind to the checkpoint receptors found on immune cells and deactivate them. Several inhibitors of these checkpoint molecules are approved for cancer treatment, including the PD-1 inhibitors Keytruda (pembrolizumab) and Opdivo (nivolumab), the <
Subscribe or to access all post and page content.